Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …
[HTML][HTML] Neutralizing monoclonal antibodies for treatment of COVID-19
PC Taylor, AC Adams, MM Hufford… - Nature Reviews …, 2021 - nature.com
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …
Tackling COVID-19 with neutralizing monoclonal antibodies
Monoclonal antibodies (mAbs) have revolutionized the treatment of several human
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …
Monoclonal antibody therapies against SARS-CoV-2
Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic
SARS-CoV-2 antibody therapeutics are being evaluated in clinical and preclinical stages. As
of 11 October 2020, 13 human monoclonal antibodies targeting the SARS-CoV-2 spike …
of 11 October 2020, 13 human monoclonal antibodies targeting the SARS-CoV-2 spike …
Monoclonal antibodies against SARS-CoV-2: current scenario and future perspectives
E Quiros-Roldan, S Amadasi, I Zanella, M Degli Antoni… - Pharmaceuticals, 2021 - mdpi.com
Monoclonal antibodies (mAbs) have been known since the 1970s. However, their
therapeutic potential in the medical field has recently emerged, with the advancement of …
therapeutic potential in the medical field has recently emerged, with the advancement of …
Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy
C Cruz-Teran, K Tiruthani, M McSweeney, A Ma… - Advanced drug delivery …, 2021 - Elsevier
To address the COVID-19 pandemic, there has been an unprecedented global effort to
advance potent neutralizing mAbs against SARS-CoV-2 as therapeutics. However, historical …
advance potent neutralizing mAbs against SARS-CoV-2 as therapeutics. However, historical …
Therapeutic monoclonal antibodies for COVID-19 management: an update
VP Chavda, R Prajapati, D Lathigara… - Expert opinion on …, 2022 - Taylor & Francis
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
affected more than 529 million people, and today the world is facing different mutant strains …
affected more than 529 million people, and today the world is facing different mutant strains …
COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19
Facing the COVID-19 global healthcare crisis, scientists worldwide are collaborating to
develop prophylactic and therapeutic interventions against the disease. Antibody …
develop prophylactic and therapeutic interventions against the disease. Antibody …
SARS-CoV-2 neutralizing antibodies for COVID-19 prevention and treatment
D Li, GD Sempowski, KO Saunders… - Annual review of …, 2022 - annualreviews.org
Prophylactic and therapeutic drugs are urgently needed to combat coronavirus disease
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …